BACKGROUND Ambiguous histopathologic diagnoses represent a challenge for clinicians because of a lack of definitive diagnosis and related uncertainty about management.
This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. The authors have indicated no significant interest with commercial supporters. E arly detection of melanoma is key from a patient prognosis standpoint, and as such the authors rely on an accurate histopathological assessment. Most histological diagnoses involving melanocytic lesions can be made with a high level of certainty, reproducibility, and agreement among dermatopathologists; however, there exists a subset of melanocytic neoplasms that can be difficult to classify as benign or malignant based on conventional microscopic analysis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] These lesions are often referred to as atypical melanocytic proliferations.
When evaluating an atypical melanocytic proliferation, pathologists may not be able to establish a definitive diagnosis and/or disagree with each other on the nature of the tumor. A lack of standardized diagnostic terminology makes it challenging to gauge clinical behavior and guide treatment. 11 Atypical melanocytic proliferations often involve expert consultation and require management based on a review of the clinical situation and favored opinions by pathologists. There is a paucity of literature on these lesions and their management. There is risk of overand undertreating patients with ambiguous melanocytic tumors because it is implicitly not known which lesion is benign and which is malignant. Here, the authors present a review of the literature on atypical melanocytic proliferations, including the current consensus on nomenclature, diagnosis, biologic potential, and treatment. Atypical melanocytic proliferations may also be seen in the nail unit and represent a separate diagnostic and therapeutic dilemma.
Nomenclature

Key Points
(1) Multiple descriptive terms representing histologically ambiguous melanocytic proliferations are used to refer to lesions that do not clearly fit into a "benign" or "malignant" category (Table 1) . (2) Inconsistent nomenclature that varies by institution may lead to patient/provider confusion and a lack of consensus on how to manage these lesions. (3) Imprecise terminology and evasion of a specific diagnosis should be avoided because there is risk of misunderstanding by clinicians, who may then opt for the wrong treatment option.
There is no established nomenclature for how to refer to lesions whose histological features do not fit into a "benign" or "malignant" category. In the literature, a variety of terms have been used, such as "atypical intraepidermal melanocytic proliferation" (AIMP), [12] [13] [14] [15] [16] "borderline melanocytic tumor" (BMT) with intraepidermal and dermal variants, [17] [18] [19] [20] [21] [22] [23] "de novo intraepidermal melanocytic dysplasia" (DNIEMD), 24, 25 "atypical junctional melanocytic hyperplasia" (AJMH), [26] [27] [28] [29] "pagetoid melanocytic proliferation"
(PMP), 26, 30 and "minimal deviation melanoma"
(MDM). [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Of these terms, one of the most commonly used is AIMP. It is used as a descriptive term for a diagnostic problem when unable to exclude melanoma in situ (MIS). 43, 44 The term AIMP may be used because the available material or clinical information is inadequate (small partial biopsy with no knowledge of clinical size and appearance of a lesion) ( Figure 1A ). Throughout this article, atypical melanocytic lesions are referred to by the terminology used in the original studies. Table 1 provides a quick reference for the terms and their definitions.
In 2004, Elder and Xu proposed to classify atypical melanocytic lesions into 2 broad categories based on the risk assessment: "superficial atypical melanocytic proliferations of uncertain significance" (SAMPUS), [43] [44] [45] [46] [47] MELTUMP Atypical melanocytic lesion with a thick dermal component, prognostically indeterminate
and "melanocytic tumors of uncertain malignant potential" (MELTUMP) ( Table 1) . With superficial tumors the risk of adverse outcome is low, whereas a thick tumor has a greater chance for harm to the patient, if the tumor is indeed a melanoma. Melanocytic tumors of uncertain malignant potential is a term that is used by pathologists for melanocytic tumors with an intradermal component if, for whatever reasons, they cannot render a definitive diagnosis and cannot exclude invasive melanoma. Atypical melanocytic lesions with a thick dermal component have also been referred to as dermal BMT. An alternate analogous approach would be to simply report tumor thickness and/or other prognostic features. These proposals essentially bypass the need for a diagnosis and address the prognosis of the worst-case scenario, that is, if the lesion was a melanoma. Terms such as SAMPUS or MELTUMP are associated with the risk of overuse by pathologists to avoid establishing a firm diagnosis for various reasons.
The presence of multiple descriptive terms that represent the same entity (a histologically ambiguous melanocytic proliferation) contributes to the confusion on the side of clinicians and patients and related uncertainty for how to manage these lesions. 50 This proposal is well-intended, but it remains doubtful to what extent the unknown can rationally be subclassified. Furthermore, evidence-based data on the utility of this schema for patients are lacking. Atypical melanocytic lesions (Variable Classification) are broadly mapped to a range from Class 2 to Class 5, which highlights the uncertainty in optimal management of these lesions. In addition, this schema may lead to unnecessary reexcision of Spitz nevi without atypia and blue nevus without atypia, and wider excision of special site nevi (acral, genital, flexural, etc.), which are mapped from Class 1 to Class 2.
Epidemiology
The incidence of atypical melanocytic proliferations is unknown because of the absence of a histopathological diagnosis code and the variable nomenclature among institutions; however, these lesions are not uncommon in clinical practice. 51 A retrospective review of 400 cases of intradermal nevi found that 25 cases (6.2%) had features of AJMH. 51 Studies have demonstrates subtle focal findings of atypical melanocytes confined to the epidermis; although lentigo maligna could not be ruled out, criteria for melanoma in situ were not met.
described a high percentage of these lesions on the lower extremities of women. [52] [53] [54] In a retrospective study of 263 skin biopsies diagnosed as DNIEMD, 82% of lesions were found in women and 71% of all lesions were on lower extremities. 25 The frequency of using ambiguous terms is, of course, highly dependent on the pathologist(s) involved in such series. Some dermatopathologists strive to render precise diagnoses on melanocytic lesions in nearly all of their reports, whereas others have a tendency to avoid specific diagnoses and/or frequently prefer reporting a diagnostic problem instead of making a diagnostic decision.
Diagnosis
Key Points
(1) Hematoxylin and eosin sectioning remains the gold standard in evaluating melanocytic lesions. (2) Even experienced dermatopathologists may at times be unable to establish a definitive diagnosis with light microscopy alone. (3) Immunohistochemistry, cytogenetic studies, and gene expression assays have emerged as potential adjuncts to improve diagnostic accuracy.
The histological descriptions of AIMP and SAMPUS refer to melanocytic proliferations confined to the epidermis or epidermis and superficial dermis, respectively. Histologically, it is not immediately clear whether a lesion is a subtle MIS, a junctional nevus with atypical features, or benign melanocyte hyperplasia. A few pagetoid melanocytes, for example, may be seen above the dermal-epidermal junction. There may also be some inflammation or subtle features of irritation, making the pathologist wonder whether the pagetoid melanocytes reflect MIS or a pseudo-melanomatous change of a nevus secondary to inflammation or external trauma. If the pathologist cannot reach a final conclusion, the default option may be a descriptive report of "AIMP" ( Figure 1B ). Another feature that may lead to an uncertain diagnosis is when a nevus is associated with a more complex growth pattern and stromal fibrosis.
Morphologic evaluation on hematoxylin and eosin sectioning is paramount and remains the gold standard in the evaluation of melanocytic lesions. 51, 55 Although reliable parameters exist for the distinction of the majority of melanomas from most nevi, even experienced dermatopathologists may at times not be able to establish a definitive diagnosis based on light microscopic parameters alone. Limits to histologic evaluation include the growing trend toward increasingly smaller biopsies (sampling error). Although less cosmetically pleasing, a larger biopsy may be necessary to yield a definitive diagnosis (Figure 2 ), as evidenced by high rates (12%-16%) of MIS upstaged to invasive melanoma in final excision specimens. 56, 57 There are several noninvasive methods to facilitate diagnosis, such as the use of a Woods lamp, dermoscopy, or confocal microscopy. These methods are valuable, but limited to user expertise and device availability, and histologic examination remains the criterion standard.
58-62
Additional boundaries to histologic diagnosis include a lack of specificity and sensitivity of some of the morphologic features used for the diagnosis of melanoma, leading to interobserver variability. Sometimes, what one pathologist may call atypical, another may call benign or malignant. [63] [64] [65] [66] At the XXIX Symposium of the International Society of Dermatopathology in 2008, international experts in dermatopathology were asked to evaluate 57 cases previously deemed MELTUMP in an effort to obtain histopathologic criteria that could reliably classify atypical melanocytic tumors as benign or malignant. There was no good consensus. Diagnostic agreement was reached in only 30% of cases. In addition, pathologists incorrectly classified 53% of cases who had a favorable outcome as malignant and 27% of cases who had an unfavorable outcome (local recurrence, Figure 2 . Subsequent larger tissue sample of specimen in Figure 1 (hematoxylin and eosin, original magnification ·10) confirms the diagnosis of melanoma in situ. Cytogenetic studies hold greater promise. Comparative genomic hybridization identifies genome-wide chromosomal alterations in cancerous lesions. Arraybased CGH, first introduced in 1998, 70 has largely replaced whole-genome CGH. It is more sensitive, technically easier to perform, and allows for detection of smaller or more focal alterations, providing a much higher resolution. 71 Bastian and colleagues pioneered the application of this technique to melanoma; the most common chromosomal aberrations found in melanoma and distinct from melanocytic nevi were loss of 9q and 10, and gains in 7. [72] [73] [74] Further studies have also found marked differences in the genetic makeup of melanomas based on anatomical location and sun-exposure pattern. 73, 75 The estimated sensitivity and specificity of this technique for melanoma are 80% to 90%. 71 False-negative results may occur because of failure of CGH to detect genomic aberrations in small populations of tumoral cells.
76
The 4-probe FISH assay has also shown promise as an ancillary diagnostic tool. 77, 78 As most melanomas have copy-number increases of 11q and 6p, to differentiate from common nevi, the initial assay combined 4 probes targeting genes on 6p25, 6q23, 11q13, and centromere 6. The initial assay had 87% sensitivity and 95% specificity for melanoma and identified 6 of 6 cases as melanomas that were histologically ambiguous and subsequently metastasized. 79 Additional validation studies found an estimated sensitivity of 80% to 100% and specificity of 95% for melanoma. 71 Another potential diagnostic adjunct is a gene expression signature that aims to differentiate benign and malignant melanocytic neoplasms. In a cohort of 437 samples that included a broad spectrum of melanocytic lesions, some of which were ambiguous, the 23-gene probe had a sensitivity of 90% and a specificity of 91% for differentiating benign nevi from primary malignant melanoma. 87 Another biomarker currently under evaluation to aid in the diagnosis of melanoma is BRCA1-associated protein 1 (BAP-1), a tumor suppressor gene. Both somatic and germline mutations in BAP-1 have been described in various tumors, including cutaneous and uveal melanomas, atypical cutaneous melanocytic tumors, mesothelioma, renal cell carcinoma, and lung adenocarcinoma. 98 Germline mutations in BAP-1, known as BAP-1 tumor syndrome, confer inherited susceptibility to the aforementioned cutaneous and internal malignancies. 99 Loss of BAP-1 expression can be identified in melanocytic lesions with IHC analysis 100 and may prove most useful in evaluation of atypical spitzoid melanocytic proliferations. [101] [102] [103] BAP-1 expression is also being evaluated as a potential prognostic marker for melanoma, especially uveal melanoma. [104] [105] [106] These molecular approaches have substantial potential to impact the management of melanocytic lesions of uncertain malignant potential, especially if histopathologic features are less than definitive. Combining multiple diagnostic modalities, such as dermatoscopy, histology, and molecular tools, has shown promise in enhancing early detection of melanomas. 107, 108 However, all of these applications require further validation studies, with long-term follow-up. A comparison of the molecular approaches is presented in Table 2 .
Progression to Invasive Malignancy
Key Points Few studies have investigated the biologic potential of atypical melanocytic proliferations. It is possible that most lesions currently reported as atypical melanocytic proliferation (AIMP or SAMPUS) are in fact benign, and that their significance lies in the potential pitfall for overdiagnosis of malignant melanoma. 26, 54 This hypothesis is based on the fact that the majority of the lesion lies intraepithelial with a minor dermal component; thus, the chance of distal metastasis is low. 44 However, a retrospective analysis of 306
AIMPs treated by conventional excision found a change in final diagnosis from AIMP to melanoma in 4.2% (13/306) after complete histopathological evaluation of the excisional specimen, 13 suggesting that a subset of these lesions are melanomas when completely sampled and reviewed. Of these melanomas, 85% were in situ and 15% were invasive. Specific risk factors associated with diagnostic change included location on the head and neck or acral areas, extension of AIMP to the base of the biopsy specimen, biopsy performed through punch technique, and an initial histopathologic differential diagnosis of melanoma. The authors recommend that for AIMPs with these features, clinicians should counsel patients on their increased risk of upstaging to melanoma before excision and consider treating similar to MIS. 13 One small study investigated the prognostic significance of AJMH by reviewing biopsies between 2003 and 2004 from a private dermatopathology laboratory. There were 27 cases that fit into the strict criteria of AJMH; of these cases, 19 were available for followup. Sixteen patients had been treated with re-excision of their lesions with 5-mm margin, and 3 patients had a re-excision with a 1-mm margin. No upstaging was described for any of these patients. All 19 patients were followed for a period of 2 to 6 years, and no recurrences occurred. 53 A retrospective analysis of 82 skin biopsies diagnosed as DNIEMD found that 8 of the lesions (9.8%) occurred in the context of fully evolved melanoma. 24 Overall, the authors determined that DNIEMDs are a distinct entity, associated with the atypical mole phenotype and a personal and/or family history of melanoma. Similar results were found in a larger retrospective review of 263 skin biopsies diagnosed as DNIEMD. 25 This study described an increased association of DNIEMD with malignant melanoma, dysplastic nevi, and nonmelanoma skin cancer. The authors proposed that these lesions might represent a transitional or evolutionary step to MIS, and/or a de novo precursor lesion to melanoma. 24 In addition, the positive association between these lesions, dysplastic nevi, and melanoma suggests that they may serve as a marker for increased risk of developing melanoma. 25 The risk of metastatic spread is higher for lesions with a largely dermal component (those categorized as MELTUMP or dermal BMT). One prospective study followed 32 patients with BMTs whom underwent wide local excision and sentinel lymph node biopsy (SLNB) with a mean follow-up of <5 years, and the study concluded that the dermal variant of these lesions can have lymph node spread and progression of disease if not adequately treated. 17 Retrospective reviews of MELTUMP tumors have reported that the risk of developing regional metastases or death from metastasized disease ranges from 1.0% to 2.4%. 52, 109 One retrospective study described lymphatic invasion 
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in 25% of patients and a statistically significant association between MELTUMP lymphatic invasion and melanoma metastases or melanoma-related death. 11 Although a number of MELTUMPs have been reported to be associated with melanocyte deposits in lymph nodes, 67 it is important to recognize that regional lymph node involvement does not constitute proof of malignancy, as there are reports of benign melanocytic nevi spreading to lymph nodes and/or cutaneous lymphatics. 44 Many MELTUMPs with positive lymph nodes are associated with a subsequent indolent clinical course.
An overview of the published data evaluating atypical melanocytic proliferations is presented in Table 3 .
Management
Key Points
(1) The malignant potential of atypical melanocytic proliferations is unknown; there are no evidencebased surgical guidelines. Medicolegal disputes in dermatopathology are often related to delayed diagnosis or misdiagnosis of melanoma. 110 As a result, there is an increasing push to diagnose melanoma early. Although less catastrophic than misdiagnosing a melanoma, there are still consequences to overdiagnosis, including increased health care expenditures, patient distress, and increased morbidity associated with unnecessary treatment.
Invasive treatments, such as large surgical excision, SLNB, lymphadenectomy, and systemic chemotherapy, have all been described for the management of atypical melanocytic lesions of uncertain malignant potential. 111, 112 As the malignant potential is unknown, there are no evidence-based surgical guidelines. Most lesions may be initially sampled with shave or incisional biopsies; however, these techniques may not capture the entire breadth of the clinical lesion. 113 To achieve the most accurate diagnosis, it is recommended that, if possible, the entire lesion be sampled for histopathologic review. This of course may be limited because of cosmetic or anatomical considerations. For lesions on the trunk, saucerization technique may be used to facilitate pathologic assessment without impairing further appropriate management such as staging. When faced with a large pigmented lesion on the face suspicious for lentigo maligna (LM), broad superficial shave biopsy or multiple small biopsies of morphologically distinct regions are preferred. These techniques maintain cosmesis while providing broad areas for histologic assessment and rarely affect future management including staged excision. 114 However, if the diagnosis is equivocal, a further biopsy may aid in the diagnosis.
The pathology report should be as precise as possible. If one pathologist cannot reach a diagnosis, it is best to consult with a more experienced colleague or several colleagues. If consensus cannot be reached or if there is agreement that the morphologic features are too ambiguous, ancillary studies may be helpful for an accurate diagnosis. If, despite ancillary studies, a definitive diagnosis cannot be established, it is preferable for the pathologist to at least favor whether or not the lesion is more likely benign or indolent versus malignant and capable of harming the patient. In the latter case, one may report thickness and other parameters as if the lesion was a melanoma.
The lesion should be managed with sufficient therapy for the most clinically significant entity in the differential diagnosis, 115 and the uncertainty and difficulty in categorizing the lesion with presently available means should be shared with the patient. 43 An open The use of topical 5% imiquimod cream has been investigated as potential adjuvant treatment for LM after surgical resection, in which histologic analysis showed persistent involvement of LM at the peripheral margin. To date, no randomized, prospective trial has been performed to determine the efficacy of topical imiquimod cream as an adjunct to surgical resection of LM. One retrospective cohort study found that 94.4% of patients who used imiquimod as adjuvant therapy after surgery demonstrated clearance of LM after a mean follow-up of 43.1 months. 120 This cohort of patients included cases of AIMP in which "early or evolving LM" was included in the diagnosis. These findings support the consideration of adjuvant therapy in cases where atypical melanocytic proliferations are seen at peripheral margins on patients with a background of sun-damaged skin, or in cases where patients are poor surgical candidates.
In cosmetically concerning areas, the use of Mohs micrographic surgery or staged excision with circumferential margin assessment may warrant consideration. In a retrospective analysis of 413 AIMPs treated with conventional excision, Zhang and colleagues 12 found that AIMPs on the head/neck, especially those with a preoperative histologic diagnosis of MIS on the differential, were associated with a higher frequency (12.5%, 4/32) of incomplete removal after conventional excision. The authors hypothesized that a preoperative diagnosis of AIMP may have been due to inadequate sampling of MIS, or that there is similar clinical behavior between AIMP and MIS. There was no significant difference in the frequency of positive or equivocal margins based on size of surgical margins for lesions on the head/neck compared with those on the trunk/extremities. An increased rate of incomplete excision was also seen for AIMPs on acral surfaces; however, this result was not statistically significant.
12
Clinicians may consider treating AIMPs at higher risk of diagnostic change to melanoma (those on the head/ neck and/or those with preoperative diagnosis of MIS on the differential) similar to an MIS in the same anatomic location. Upstaging of AIMP to melanoma after conventional excision is important, as it will increase the risk of subsequent melanoma and alter follow-up recommendations. 124 The general consensus for atypical melanocytic lesions with a largely dermal component, e.g., MELTUMPs, is treatment as malignant melanoma because of the aforementioned potential for lymph node involvement, invasion of cutaneous lymphatic vessels, and distant metastases. 7, 43, 44, 52, 116, [125] [126] [127] Close consideration should be given to lesion characteristics, sufficient sampling, patient characteristics, and ancillary diagnostic techniques, such as CGH and FISH before invasive adjuncts, such as SLNB.
11,128
Conclusion
The authors' review of the literature of atypical melanocytic proliferations highlights the overall ambiguity of these lesions and the potential pitfalls that they present, including, but not limited to, diagnostic disagreement, institutional variations in nomenclature, uncertain biologic potential, and lack of histologic criteria, and management recommendations. To improve diagnostic specificity, stronger efforts are
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needed to improve ancillary methods for when light microscopy fails.
The various terms and abbreviations for atypical melanocytic lesions (Table 1) are not always well defined or easily used in clinical parlance, and improved characterization of these lesions represents a major gap in the literature. The inconsistent nomenclature highlights 2 points: (1) imprecise terminology should be avoided because it is critical to establish a diagnosis as definitive as possible by obtaining second or third opinions and using ancillary studies when appropriate, and (2) irrespective of the descriptive terminology used, these terms suggest an uncertain prognosis, warranting complete sampling of the clinical lesion when possible. Communication between the pathologist and treating clinician is essential for clinicopathologic correlation.
In addition, the authors' review highlights the importance of having an open discussion with patients in regards to the management of these lesions. The decision to re-biopsy, excise, or monitor may vary depending on the aforementioned factors. Optimal margins may differ in the size based on anatomic location. Although reported rates of upstaging to frank melanoma are low, there is a paucity of published data in this area, and invasion, lymph node spread, and metastasis can occur. Additional studies showing long-term outcomes, recurrence, and progression to melanoma are needed to determine the biologic potential of these lesions and to further guide clinical management.
